Overview

Cancer is one of the leading health challenges worldwide. While specific global figures for 2025 are still projections, the most recent consolidated data from the World Health Organization (WHO) and its agencies indicate that in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths globally. Cancer is projected to remain the second leading cause of death globally, with mortality rates continuing to be a major public health concern despite treatment advancements.
The Global Oncology Drug Market is poised for substantial growth, estimated to have reached approximately $320.3 billion in 2024 and is forecast to grow to around $345.1 billion in 2025, reflecting a significant increase from the $133 billion reported in 2017.

Over the past decade, the paradigm shift in the treatment of cancer, driven by advances in personalized medicine and immuno-oncology, has accelerated. From 2017 through the first half of 2025, numerous novel therapies have been launched globally, with new oncology drug approvals by the FDA, including many first-in-class therapeutics.

These developments have led to improved outcomes for patients, especially for metastatic disease, and have led to an increased number of patients receiving treatment. The success of new modalities continues to redefine therapeutic strategies across multiple tumor types.
The global R&D pipeline for oncology remains extremely robust, with a continuously increasing number of compounds in development. While precise late-stage breakdowns for 2025 are dynamic, current trends highlight a substantial shift towards more complex modalities. The pipeline is heavily invested in biologics and small molecules, particularly those involved in targeted therapy and immunotherapy pathways.